0.060
0.01 (16.28%)
| Penutupan Terdahulu | 0.052 |
| Buka | 0.052 |
| Jumlah Dagangan | 92,282 |
| Purata Dagangan (3B) | 322,306 |
| Modal Pasaran | 2,022,527 |
| Harga / Pendapatan (P/E TTM) | 0.000 |
| Harga / Pendapatan (P/E Ke hadapan) | 0.370 |
| Harga / Jualan (P/S) | 660.53 |
| Harga / Buku (P/B) | 0.610 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 Aug 2025 - 22 Aug 2025 |
| EPS Cair (TTM) | -6,321.50 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.34% |
| Nisbah Semasa (MRQ) | 0.250 |
| Aliran Tunai Operasi (OCF TTM) | -14.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.41 M |
| Pulangan Atas Aset (ROA TTM) | -53.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -124.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Windtree Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.01% |
| % Dimiliki oleh Institusi | 1.39% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |